Redefining approaches in early lines of multiple myeloma
DARZALEX® (daratumumab) has proven efficacy and safety across multiple regimens and lines of therapy1
MM=mulitple myeloma; Pd=pomalidomide (P) + dexamethasone (d); Rd=lenalidomide (R) + dexamethasone (d); Vd=bortezomib (V) + dexamethasone (d); VMP=bortezomib (V) + melphalan (M) + prednisone (P); VTd=bortezomib (V) + thalidomide (T) + dexamethasone (d).
†Prior therapies included lenalidomide and a proteasome inhibitor (PI).
‡Prior therapies included a PI and an immunomadulatory agent, or patients were double-refractory to a PI and an immunomodulatory agent.